Efficacy of cevimeline vs. pilocarpine in the secretion of saliva: a pilot study

Brimhall, Jae; Jhaveri, Malhar A.; Yepes, Juan F.

doi:10.1111/scd.12010

Cited by 31 publications

(21 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In treatment of xerostomia, sialagogues especially anticholinergic: pilocarpine, cevimeline and bromhexine drugs are recommended. Efficacy of pilocarpine (5 mg three times a day) and cevimeline (30 mg three times a day) in secretion of saliva is similar but cevimeline has less side-effects particularly in long-lasting therapy [17,18].…”

Section: Discussionmentioning

confidence: 99%

Oral mucosal manifestations in primary and secondary Sjögren syndrome and dry mouth syndrome

Błochowiak¹,

Olewicz‐Gawlik²,

Polańska³

et al. 2016

pdia

View full text Add to dashboard Cite

Introduction One of the most important symptoms of Sjögren syndrome is xerostomia. The oral cavity deprived of saliva and its natural lubricative, protective and antibacterial properties is prone to a number of unfavourable consequences. Aim To present the most important lesions on the oral mucosa in primary and secondary Sjögren syndrome and in dry mouth syndrome. Material and methods The study group comprised 55 patients including 52 women and 3 men aged 20–72 years (average: 28.25 years). Results Basing on the accepted criteria, primary Sjögren syndrome was diagnosed in 22 (40%) patients, secondary Sjögren syndrome in 18 (32.7%) patients, and dry mouth syndrome in 15 (27.27%) patients. The physical examination and the examination of the mouth were performed and history was elicited from every patient. Conclusions The most common pathologies appearing on the oral mucosa in primary and secondary Sjögren syndrome are angular cheilitis, cheilitis, increased lip dryness as well as non-specific ulcerations, aphthae and aphthoid conditions.

show abstract

Section: Discussionmentioning

confidence: 99%

Oral mucosal manifestations in primary and secondary Sjögren syndrome and dry mouth syndrome

Błochowiak¹,

Olewicz‐Gawlik²,

Polańska³

et al. 2016

pdia

View full text Add to dashboard Cite

show abstract

“…In 17.6% of the patients cevimeline-related toxicity was the reason for abandoning the study medication. Recently, cevimeline was compared with oral pilocarpine in a small randomized, cross-over, double blind study, showing a slightly higher, though non-significant, incremental increase in saliva production at the end of four weeks with pilocarpine [41]. …”

Section: Xerostomiamentioning

confidence: 99%

Treatment of late sequelae after radiotherapy for head and neck cancer

Strojan

Hutcheson

Eisbruch

et al. 2017

Cancer Treatment Reviews

226

160

View full text Add to dashboard Cite

Radiotherapy (RT) is used to treat approximately 80% of patients with cancer of the head and neck. Despite enormous advances in RT planning and delivery, a significant number of patients will experience radiation-associated toxicities, especially those treated with concurrent systemic agents. Many effective management options are available for acute RT-associated toxicities, but treatment options are much more limited and of variable benefit among patients who develop late sequelae after RT. The adverse impact of developing late tissue damage in irradiated patients may range from bothersome symptoms that negatively affect their quality of life to severe life-threatening complications. In the region of the head and neck, among the most problematic late effects are impaired function of the salivary glands and swallowing apparatus. Other tissues and structures in the region may be at risk, depending mainly on the location of the irradiated tumor relative to the mandible and hearing apparatus. Here, we review the available evidence on the use of different therapeutic strategies to alleviate common late sequelae of RT in head and neck cancer patients, with a focus on the critical assessment of the treatment options for xerostomia, dysphagia, mandibular osteoradionecrosis, trismus, and hearing loss.

show abstract

“…Stimulation of salivary gland function may be appropriate for patients with some degree of residual salivary gland parenchyma, and it can be attempted through sialogogue medications (such as pilocarpine and cevimeline) [4], or activating the salivary reflex arch via chewing gums or sucking pastilles and lozanges [5]. Topical application of salivary substitutes can offer some benefit by providing a moistureretaining coating onto the oral mucosa [6].…”

Section: Introductionmentioning

confidence: 99%

Interventions for the management of radiotherapy-induced xerostomia and hyposalivation: A systematic review and meta-analysis

et al. 2017

View full text Add to dashboard Cite

show abstract

Efficacy of cevimeline vs. pilocarpine in the secretion of saliva: a pilot study

Abstract: Both medications increased the secretion of saliva at the end of four weeks. However, there was a slightly higher increment in saliva with pilocarpine. However, the difference was not statistically significant.

Cited by 31 publications

References 12 publications

Oral mucosal manifestations in primary and secondary Sjögren syndrome and dry mouth syndrome

Oral mucosal manifestations in primary and secondary Sjögren syndrome and dry mouth syndrome

Treatment of late sequelae after radiotherapy for head and neck cancer

Interventions for the management of radiotherapy-induced xerostomia and hyposalivation: A systematic review and meta-analysis

Contact Info

Product

Resources

About